QNTM Labs ApSAktiv

The company conducts testing, analysis, and research of pharmaceutical products for Danish, European, and global markets.

Development in activities and financesAt QNTM Labs, 2025 was a year of continued development by growth of revenue and additional positive operational momentum. As a GMP-certified Quality Control (QC) laboratory serving the biopharmaceutical industry, we remained focused on delivering dependable, high-quality GMP analytical testing services, supported by a strong emphasis on customer needs and regulatory compliance. ​​Throughout the year, we strengthened our collaboration with key customers and the operational platform through ongoing investments in people, laboratory capabilities, and infrastructure. Our culture continues to be defined by scientific rigor, transparency, effective communication, and a collaborative work environment that supports flexibility, engagement, and well-being. These foundations enable us to build lasting partnerships with our customers and support their long-term success. ​​Although the company is still in a scaling phase, 2025 demonstrated encouraging progress toward improved utilization and revenue development. Continuous improvements have contributed to greater operational stability,​positioning QNTM Labs more effectively for sustainable growth. Achieving full operational profitability remains a key objective and will require continued execution and focus. ​​In 2026, QNTM Labs will prioritize commercial expansion by deepening collaboration with existing customers while actively broadening the customer portfolio. At the same time, we will work to in

Uddrag af ledelsesberetningen i den seneste årsrapport.